检索结果-南通市图书馆

冷酷“脚手架”——新加坡Durasafe零售商店

在线全文

学校读者我要写书评

暂无评论

设计家 2013年第6期 94-97页

作者： Colin seah tan Qing ling lolleth Alejandro Don Washington Castaneda Ron sim charissa Ho 张妍钰 Ministry of Design

Durasafe是新加坡一家供应安全装备的品牌商,此次旗舰店的设计,商家希望可以打造一个独特的商品展示和零售的空间,既能加强已有的品牌形象,又能为该品牌主要的男性客户群提供一个兴奋的购物体验。项目位于一个6米高的现代仓库,于是设计... 详细信息

Durasafe是新加坡一家供应安全装备的品牌商,此次旗舰店的设计,商家希望可以打造一个独特的商品展示和零售的空间,既能加强已有的品牌形象,又能为该品牌主要的男性客户群提供一个兴奋的购物体验。项目位于一个6米高的现代仓库,于是设计师试图创造一个多层次的空间体验,为整个购物过程增添一点戏剧化的效果。

关键词：零售商店新加坡脚手架品牌形象空间体验安全装备商品展示设计师

在线全文

学校读者我要写书评

暂无评论

城市母亲对学前儿童社会化发展的信念

学前教育研究 2017年第11期 48-57页

作者：胡芳谢庆斌李燕徐虔凯瑞莎·陈上海师范大学教育学院上海200234 University of Maryland Baltimore County Baltimore USA

以上海市216名中班儿童母亲(男孩母亲112名,女孩母亲104名)为研究对象,本研究采用访谈法,通过三个假想情境调查母亲对学前儿童三种社会技能(分享、控制消极情绪、助人)的社会化目标、社会化归因和社会化策略的信念,结果表明在社会化目标... 详细信息

以上海市216名中班儿童母亲(男孩母亲112名,女孩母亲104名)为研究对象,本研究采用访谈法,通过三个假想情境调查母亲对学前儿童三种社会技能(分享、控制消极情绪、助人)的社会化目标、社会化归因和社会化策略的信念,结果表明在社会化目标上,超过一半的母亲认为分享和助人的重要性显著高于控制消极情绪,因为分享和助人行为是符合社会传统习俗和道德品质要求的表现,而控制消极情绪则是随着幼儿年龄增长而自然发展的;在社会化归因上,母亲认为幼儿出现助人行为和能够控制消极情绪主要是受社会规范或道德要求等外部因素的影响。对于分享行为,男孩母亲在内外两种归因上差异不显著,女孩母亲则倾向于外部归因;在社会化策略上,大部分母亲都报告她们倾向于使用以幼儿为中心的引导策略,而最不倾向于使用父母权威的教导策略。

关键词：社会化信念社会化目标社会化归因社会化策略

Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第20期21卷 6236-6245页

作者： Kieron Bl lim Hamid R sima M Isabel Fiel Viktoriya Khaitova John T Doucette Maria Chernyiak Jawad Ahmad Nancy Bach charissa Chang Priya Grewal leona Kim-schluger lawrence liu Joseph Odin Ponni Perumalswami sander s Florman Thomas D schiano Division of liver Diseases Icahn School of Medicine at Mount Sinai Division of Gastroenterology and Hepatology National University Center for Organ TransplantationNational University Hospital lillian and Henry M stratton-Hans Popper Department of Pathology Icahn School of Medicine at Mount Sinai Recanati-Miller Transplantation Institute Icahn School of Medicine at Mount Sinai Department of Preventive Medicine Icahn School of Medicine at Mount Sinai

AIM: To describe our experience using a low-acceleratingdose regimen(lADR) with pegylated interferon alpha-2a and ribavirin in treatment of hepatitis C virus(HCV) recurrence. METHODs: From 2003, a protocolized lADR strategy was employed to treat liver transplant(lT) recipients with recurrent HCV at our institution. Medical records of 182 adult patients with recurrent HCV treated with lADR between 1/2003 and 1/2011 were reviewed. Histopathology from all post-lT liver biopsies were reviewed in a blinded fashion. Paired recipient and donor Il28 B status were assessed. A novel technique was employed to ascertain recipient and donor Il28B(rs12979860) Gt data using DNA extracted from archival FFPE tissue from explanted native livers and donor gallbladders respectively. The primary endpoint was sVR; secondary endpoints examined include(1) patient and graft survival;(2) effect of anti-viral therapy on liver histology(fibrosis and inflammation);(3) incidence of on-treatment development of ACR, CDR, or PCH;(4) association of recipient and donor Il28 B genotype with sVR; and(5) incidence of antiviral therapy-associated adverse events(anemia, leukopenia, thrombocytopenia, depression) and hepatic ***: The overall sVR rate was 38%(29% Gt1, 67% Gt2, 86% Gt3 and 58% Gt4). HCV Gt(P lovirus mismatch(P = 0.001), baseline serum bilirubin(P = 0.002), and baseline viral load(P = 0.04) were independent predictors for sVR. sVR rates were significantly higher in the recipient-CC/donor-non CC pairs(P = 0.007). Neither baseline fibrosis nor change in fibrosis stage after anti-viral therapy were associated with sVR. Fibrosis progressed in 72% of patients despite sVR. Median graft survival was 91 mo. Five-year patient survival was superior in patients who achieved sVR(97% vs 82%, P = 0.001). Pre-treatment AlP ≥ 150 U/l(P = 0.01), total bilirubin ≥ 1.5 mg/d l(P = 0.001) and creatinine ≥ 2 mg/d l(P = 0.001) were independently associated

关键词： Hepatitis C recurrence liver transplant low accelerating dose regimen Peginterferon α-2a Il28B

Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第9期22卷 2844-2854页

作者： Neal Patel Kian Bichoupan lawrence Ku Rachana Yalamanchili Alyson Harty Donald Gardenier Michel Ng David Motamed Viktoriya Khaitova Nancy Bach charissa Chang Priya Grewal Meena Bansal Ritu Agarwal lawrence liu Gene Im Jennifer leong leona Kim-schluger Joseph Odin Jawad Ahmad scott Friedman Douglas Dieterich Thomas schiano Ponni Perumalswami Andrea Branch Division of liver Diseases Icahn School of Medicine at Mount Sinai Recanati Miller Transplant Institute Icahn School of Medicine at Mount Sinai

AIM: To determine the safety profile of new hepatitis C virus (HCV) treatments in liver transplant (lT) recipients with recurrent HCV ***: Forty-two patients were identified with recurrent HCV infection that underwent lT at least 12 mo prior to initiating treatment with a sofosbuvir-based regimen during December 2013-June 2014. Cases were patients who experienced hepatic decompensation and/or serious adverse events (sAE) during or within one month of completing treatment. Controls had no evidence of hepatic decompensation and/or sAE. HIV-infected patients were excluded. Cumulative incidence of decompensation/sAE was calculated using the Kaplan Meier method. Exact logistic regression analysis was used to identify factors associated with the composite ***: Median age of the 42 patients was 60 years [Interquartile Range (IQR): 56-65 years], 33% (14/42) were female, 21% (9/42) were Hispanic, and 9% (4/42) were Black. The median time from transplant to treatment initiation was 5.4 years (IQR: 2.1-8.8 years). Thirteen patients experienced one or more episodes of hepatic decompensation and/or sAE. Anemia requiring transfusion, the most common event, occurred in 62% (8/13) patients, while 54% (7/13) decompensated. The cumulative incidence of hepatic decompensation/sAE was 31% (95%CI: 16%-41%). Risk factors for decompensation/sAE included lower pre-treatment hemoglobin (OR = 0.61 per g/dl, 95%CI: 0.40-0.88, P stimated glomerular filtration rate (OR = 0.95 per ml/min per 1.73 msup>2sup>, 95%CI: 0.90-0.99, P = 0.01), and higher baseline serum total bilirubin (OR = 2.43 per mg/dl, 95%CI: 1.17-8.65, P sustained virological response rate for the cohort of 42 patients was 45%, while it was 31% for ***: sofosbuvir/ribavirin will continue to be used in the post-transplant population, including those with HCV genotypes 2 and 3. Management of anemia remains an important clinical challenge.

关键词： Hepatitis C virus sofosbuvir Ribavirin Anemia Hepatic decompensation serious adverse event liver transplant

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

诗家董百货旗舰店

现代装饰 2014年第4期 96-101页

作者： Colin seah Kevin leong Ron sim Joyce low Don Washington Castaneda Dennis Cheok tan Qingling Julie Djohan Dora Tokai Joanne Pang charissa Ho Bryan law Allan Veloso lolleth Alejandro Edward Hendricks 姜敏华

本案获得了多个享誉盛名的专业奖项，其中包括“新加坡2013年度最佳购物体验奖”以及由新加坡零售协会颁发的“2013年度最佳零售概念奖”。MOD设计团队与新加坡的知名百货公司“诗家董”共同合作完成了此次“诗家董”店庆80周年的改造... 详细信息

本案获得了多个享誉盛名的专业奖项，其中包括“新加坡2013年度最佳购物体验奖”以及由新加坡零售协会颁发的“2013年度最佳零售概念奖”。MOD设计团队与新加坡的知名百货公司“诗家董”共同合作完成了此次“诗家董”店庆80周年的改造项目。

关键词：旗舰店新加坡改造项目百货公司 MOD 零售

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results

在线全文

学校读者我要写书评

暂无评论

World Journal of Virology 2017年第4期6卷 59-72页

作者： Kian Bichoupan Neeta tandon James F Crismale Joshua Hartman David Del Bello Neal Patel sweta Chekuri Alyson Harty Michel Ng Keith M sigel Meena B Bansal Priya Grewal charissa Y Chang Jennifer leong Gene Y Im lawrence U liu Joseph A Odin Nancy Bach scott l Friedman Thomas D schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch Division of liver Diseases Icahn School of Medicine at Mount Sinai Janssen scientific Affairs LLC Division of General Internal Medicine Icahn School of Medicine at Mount Sinai

AIM To assess the real-world effectiveness and cost of simeprevir(sMV), and/or sofosbuvir(sOF)-based therapy for chronic hepatitis C virus(HCV) *** The real-world performance of patients treated with sMV/sOF ± ribavirin(RBV), sOF/RBV, and sOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(sVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with sVR12 were identified using multivariable logistic *** sVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on sMV/sOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on sOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on sOF/PEG/RBV. Mean costs-per-sVR 12 were $174442(standard deviation: ± $18588) for sMV/sOF ± RBV; $223003(± $77946) for sOF/RBV; and $126496(± $31052) for sOF/PEG/RBV. Among patients on sMV/sOF ± RBV, sVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of sVR12 among patients on sOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of sVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on sOF/PEG/RBV. CONClUsION sVR 12 rates for sMV and/or sOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs.

关键词： Cirrhosis Cost sustained virological response Protease inhibitor Polymerase inhibitor